Lowey Dannenberg, P.C. Announces Filing of Securities Class Action Lawsuit Against Bellus Health Inc. on Behalf of Investors Who Acquired Shares from September 19, 2019 to July 5, 2020 and Encourages
- Futures firm after tax hike proposal, business activity data eyed
- Snap (SNAP) Beats Q1 Estimates Amid 'Robust Ad Environment,' Analysts Raise Numbers and PTs
- Bitcoin sinks below $50,000 as cryptos stumble over Biden tax plans
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
- Q2 Will Be a 'Pain Trade', Bonds to Outperform Stocks; Buy US Defensives - BofA
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
NEW YORK, March 17, 2021 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a securities class action in the United States District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired common stock of Bellus Health, Inc. ("Bellus" or "Company") (NASDAQ: BLU) from September 19, 2019 through July 5, 2020, inclusive (the "Class Period"). The class action alleges violations of federal securities laws.
Bellus is a clinical-stage biopharmaceutical company whose lead product is BLU-493, which is being developed for the treatment of chronic cough and other afferent hypersensitization related disorders.
The Complaint alleges Bellus made false and misleading statements in its registration statement and prospectus (the “Offering”) and in subsequent public statements throughout the Class Period and failed to disclose material adverse facts about the Company’s business. Specifically, Bellus and its senior officers (1) deceived the investing public about the efficacy of BLU-493, which created a high risk that the drug would not receive FDA approval of Phase 2 trials, and would fall further behind the industry leaders in developing a FDA-approved treatment; (2) created artificial demand for the Bellus common shares sold in the Offering, that enabled the Company to receive approximately $70 million. and (3) caused Plaintiff and the Class to purchase the Company’s publicly traded common stock at artificially inflated prices through July 5, 2020.
If you wish to serve as Lead Plaintiff for the Class, you must file a motion with the Court no later than May 17, 2021. Any member of the proposed Class may serve as the Lead Plaintiff through counsel of their choice.
If you have suffered a net loss from investment in Bellus’ initial public offering of common stock effective as of September 5, 2019, or through purchases in the secondary market through July 5, 2020, you may obtain additional information about this lawsuit and your ability to become a Lead Plaintiff by contacting David Harrison at firstname.lastname@example.org or at 914-733-7228 or Christian Levis at email@example.com or at 914-733-7220.
About Lowey Dannenberg
Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.
Lowey Dannenberg P.C.44 South Broadway, Suite 1100White Plains, NY 10601Tel: (914) 733-7228Email: firstname.lastname@example.org
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XL Fleet Corp., Bellus Health, Neptune Wellness, and Sequential Brands and Encourages Investors to Cont
- Blink Deploys IQ 200 Charging Stations at Native American Youth & Family Center in Portland, Oregon
- Second Rig on Site and Drilling to Accelerate 50,000m Exploration Campaign